New Phase II data on CEM 101 (solithromycin), from Cempra Inc, in patients with Infectious Diseases show that patients with...
Cempra Inc. has announced data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrating...
Cempra has received a Complete Response Letter (CRL) from the FDA relating to the company�s new drug applications (NDAs) for...
Cempra Inc. announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in...
Bayer and Hologic, Inc., announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions
Bayer announced that its iodine-based contrast agent Ultravist-300, -370 is now approved for contrast-enhanced mammography (CEM) in the EU
Objectives: To compare the safety and efficacy of ixekizumab, an IL-17A antagonist, with the safety and efficacy of the IL-12/23 inhibitor ustekinumab through 52 weeks of treatment in the head-to-head trial IXORA-S.
On 31 January the FDA approved Ravicti (glycerol phenylbutyrate) from Hyperion Therapeutics, for the chronic management of some Urea Cycle...
Objective: Assess the efficacy and safety of bimekizumab, a monoclonal antibody that potently and selectively neutralizes IL-17A and IL-17F, in patients with moderate-to-severe plaque psoriasis.
Objective: To evaluate the effect of guselkumab on psoriasis in specific body regions.